ASCLEPIUMM TAIWAN CO LTD has a total of 15 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2016. It filed its patents most often in China, EPO (European Patent Office) and United States. Its main competitors in its focus markets pharmaceuticals and biotechnology are LEXIGEN PHARM CORP, ALTOR BIOSCIENCE CORP and PEPTINOV SAS.
# | Country | Total Patents | |
---|---|---|---|
#1 | China | 3 | |
#2 | EPO (European Patent Office) | 3 | |
#3 | United States | 3 | |
#4 | WIPO (World Intellectual Property Organization) | 3 | |
#5 | Taiwan | 2 | |
#6 | Republic of Korea | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Peptides | |
#3 | Therapeutic chemical compounds | |
#4 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Chen Min-Che | 14 |
#2 | Chen Chun-Wei | 10 |
#3 | Chang Po-Hao | 9 |
#4 | Liu Ya-Chuan | 9 |
#5 | Tsai Ya-Ping | 5 |
#6 | Lee Pei-Yi | 5 |
#7 | Chen Chun Wei | 1 |
#8 | Chen Min Che | 1 |
Publication | Filing date | Title |
---|---|---|
WO2017211278A1 | Antibody fusion proteins for drug delivery | |
US2019177394A1 | Dsg2-derived peptides | |
EP3464355A1 | Dsg2 monoclonal antibody and use thereof |